Evidence map›Paper›PMID 40573915›Full record

ArticleVaccines2025

Pre- and Post-Vaccination Measles Antibody and Persistence Up to 5 Years of Age Among Early ART-Treated HIV-Infected, HIV-Exposed Uninfected and HIV-Unexposed Children in Cameroon.

Mathurin Cyrille Tejiokem, Emilie Desselas, Thierry Joel Noumsi, Francis Ateba Ndongo, Suzie Tetang Ndiang, Mireille Arlette Fossi, Georgette Guemkam, Berenice Zangue Kenfack Tekougang, Paul Alain Tagnouokam-Ngoupo, Ida Calixte Penda and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mathurin Cyrille TejiokemCentre Pasteur du Cameroun, Yaoundé P.O. Box 1274, Cameroon.ORCID 0000-0002-1420-9628
Emilie DesselasCentre Pasteur du Cameroun, Yaoundé P.O. Box 1274, Cameroon.
Thierry Joel NoumsiCentre Pasteur du Cameroun, Yaoundé P.O. Box 1274, Cameroon.
Francis Ateba NdongoCentre Mère et Enfant de la Fondation Chantal Biya, Yaoundé P.O. Box 1364, Cameroon.
Suzie Tetang NdiangCentre Hospitalier d'Essos, Yaoundé P.O. Box 5777, Cameroon.
Mireille Arlette FossiHôpital Laquintinie de Douala, Douala P.O. Box 4035, Cameroon.
Georgette GuemkamCentre Mère et Enfant de la Fondation Chantal Biya, Yaoundé P.O. Box 1364, Cameroon.
Berenice Zangue Kenfack TekougangCentre Pasteur du Cameroun, Yaoundé P.O. Box 1274, Cameroon.ORCID 0009-0000-3479-1793
Paul Alain Tagnouokam-NgoupoCentre Pasteur du Cameroun, Yaoundé P.O. Box 1274, Cameroon.ORCID 0000-0002-7449-5128
Ida Calixte PendaDépartement des Sciences cliniques, Faculté de Médecine et des Sciences Pharmaceutiques, Université de Douala, Douala P.O. Box 2701, Cameroon.ORCID 0000-0002-1070-2108
Albert FayeService de Pédiatrie Générale, Hôpital Universitaire Robert Debré, Assistance Publique des Hôpitaux de Paris, 75019 Paris, France.
Josiane WarszawskiCESP, INSERM, UVSQ, Université Paris-Saclay, 94807 Villejuif, France.

Funding

Agence Nationale de Recherches sur le Sida et les Hépatites Virales 12140/12225-Pediacam
6 · The paper itself

Abstract

BACKGROUND/

objectiveVariations in measles vaccine antibody response by age and HIV status have been reported. This study assessed measles pre-vaccination status and compared humoral response durability over the first five years of life among HIV-infected (HI) children on early treatment, HIV-exposed uninfected (HEU), and HIV-unexposed uninfected (HUU) children within the ANRS 12225-Pediacam III cohort in Cameroon.

methodsMeasles vaccine (MCV) was administered at 6 and 9 months for HIV-exposed infants and at 9 months for HIV-unexposed infants, followed by a measles-mumps-rubella (MMR) dose at 15 months for all. Measles antibody titers were measured pre-vaccination, 1-6 months post-MCV doses, and annually until age 5 using ELISA (Enzygnost, Dade Behring).

resultsA total of 496 children were included: 143 HI (median age at cART initiation: 4.2 months, (IQR: 3.2-5.6)), 180 HEU, and 173 HUU. Of these, 456 children were tested pre-vaccination (median age: 6.1 months, IQR: 5.6-6.8), with 6.1% (95% CI: 4.1-8.6) seropositive to measles antibodies, with differences across groups. At 18.4 months (IQR: 18.1-19.9), seropositivity rates were 96.7% (59/61) in HI, 96.8% (90/93) in HEU, and 100% (111/111) in HUU groups. For children following the 6 + 9 + 15-month or 9 + 15-month MCV schedules, seropositivity at 18, 36, 48, and 60 months was 96%, 89%, 87%, and 88%, respectively, with no significant differences between groups.

conclusionsEarly cART initiation in HI children may result in a robust initial measles antibody response, with comparable persistence of antibody titers across all groups up to five years.

Indexed as

early treated HIV-infectedHIV-exposed uninfectedHIV-unexposed uninfectedlow- and middle-income countriesmeasles humoral immunitypersistence of measles antibodiespre-measles vaccine antibodiesreal life conditions

Identifiers

PMID40573915
PMCPMC12197448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.